オプションチェーンは、GRI Bioの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、GRI Bioの市場センチメントを評価します。.

GRI Bio (NASDAQ:GRI) 株価情報, オプションチェーン

GRI Bio

Cohen & Steers Global Realty Majors ETF

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

GRI Bio Inc

First Trust NASDAQ Clean Edge Smart Grid Infrastructure Index Fund

Grid+

GRIID Infrastructure Inc

GRINDROD SHIPPING HLDGS LTD ORD

Grin

ALPS ETF Trusthen & Steers Global Realty Majors ETF

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

WIIM

GRI Bio shares are trading lower after the company announced a 1-for-17 reverse stock split.

GRI's common stock is expected to begin trading on a post-split adjusted basis on February 24, 2025
LA JOLLA, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=MzcPI4Nne-gM9Y7IcrvoQNVonsr-sxSgaMIIl8GMorqA_B5Lg8fWbPdlBY6JIGy97U4a6Zc22KT2nbZICLkmUw==">GRI Bio, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the board of directors of the Company approved a&nbsp;1-for-17 reverse stock split (the "Reverse Split") of the Company's common stock. The Reverse Split was approved by the stockholders of the Company at a special meeting of the Company held on February 11, 2025. The Reverse Split will legally take effect at 4:01 p.m. Eastern Time, on February 21, 2025. The Company's common stock will open for trading under a new CUSIP number 3622AW 403 on The Nasdaq Capital Market on February 24, 2025, on a split-adjusted basis under the current ticker symbol "GRI." The Reverse Split is intended to increase the per share trading price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

News

Stock Split

GRI Bio Announces 1-For-17 Reverse Stock Split, Expected To Begin Trading On A Post-Split Adjusted Basis On February 24, 2025

<h3>Gainers</h3>
<ul>
<li>Anitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) stock moved upwards by 89.1% to $0.53 during Tuesday's pre-market session. The company's market cap stands at $6.5 million. </li>
<li>Evaxion Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) stock increased by 60.83% to $3.86. The company's market cap stands at $24.1 million. </li>
<li>Achilles Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHL#NASDAQ">ACHL</a>) stock rose 22.32% to $1.37. The market value of their outstanding shares is at $58.5 million. </li>
<li>Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) stock moved upwards by 19.81% to $1.27. The company's market cap stands at $151.9 million. </li>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) stock rose 18.79% to $7.9. The market value of their outstanding shares is at $8.0 million. </li>
<li>Kymera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) stock rose 16.91% to $45.0. The market value of their outstanding shares is at $2.9 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock decreased by 28.4% to $0.3 during Tuesday's pre-market session. The company's market cap stands at $2.5 million. </li>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) stock fell 19.33% to $0.51. The company's market cap stands at $22.8 million. </li>
<li>LifeStance Health Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFST#NASDAQ">LFST</a>) stock decreased by 12.93% to $7.0. The market value of their outstanding shares is at $2.6 billion. </li>
<li>Omega Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) stock decreased by 12.34% to $0.42. The company's market cap stands at $23.2 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares declined by 12.04% to $0.55. The company's market cap stands at $4.9 million. </li>
<li>IMAC Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) shares decreased by 11.92% to $0.67. The market value of their outstanding shares is at $1.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ACHL

ACON

AZTR

BACK

EVAX

HCWB

IVVD

KYMR

LFST

OMGA

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Strengthening Global Patent Portfolio For NKT Cell Modulators Targeting Inflammatory And Autoimmune Diseases

GRI Bio Secures European Patent Approval For GRI-0803 And 500+ Proprietary Compounds

HC Wainwright &amp; Co. analyst Joseph Pantginis initiates coverage on GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) with a Buy rating and announces Price Target of $10.

Price Target

Initiation

Analyst Ratings

HC Wainwright & Co. Initiates Coverage On GRI Bio with Buy Rating, Announces Price Target of $10

Ascendiant Capital analyst Edward Woo maintains GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) with a Buy and raises the price target from $12 to $13.

Ascendiant Capital Maintains Buy on GRI Bio, Raises Price Target to $13

Biotech

General

GRI Bio Highlights GRI-0621's Potential To Reduce Inflammation And Hepatic Fibrosis In Idiopathic Pulmonary Fibrosis, With Positive Preclinical Data Presented At AFDD Summit And Phase 2 Topline Data Expected In Q2 2025

<h3>Gainers</h3>
<ul>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) stock increased by 71.0% to $0.32 during Friday's pre-market session. The company's market cap stands at $48.1 million. </li>
<li>QT Imaging Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTI#NASDAQ">QTI</a>) shares moved upwards by 18.58% to $0.58. The company's market cap stands at $12.4 million. As per the news, the Q3 earnings report came out 2 days ago. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares rose 18.02% to $0.77. </li>
<li>Alpha Teknova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) stock rose 14.17% to $7.49. The market value of their outstanding shares is at $399.2 million. </li>
<li>Gain Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) shares rose 14.04% to $1.99. The market value of their outstanding shares is at $50.8 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) stock increased by 14.02% to $4.96. The market value of their outstanding shares is at $4.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TFF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) shares fell 71.9% to $0.45 during Friday's pre-market session. The market value of their outstanding shares is at $1.5 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares decreased by 60.02% to $0.14. The market value of their outstanding shares is at $11.6 million. As per the news, the Q3 earnings report came out 3 days ago. </li>
<li>Akoya Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) stock declined by 31.31% to $2.15. The market value of their outstanding shares is at $106.4 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares declined by 20.85% to $0.76. The market value of their outstanding shares is at $2.8 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares declined by 17.66% to $0.3. The company's market cap stands at $1.8 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares decreased by 13.44% to $0.24. The company's market cap stands at $5.1 million. As per the news, the Q3 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKYA

CERO

CTCX

EYEN

GANX

ISPC

TCBP

TFFP

TIVC

TKNO

12 Health Care Stocks Moving In Friday's Pre-Market Session

GRI Bio shares are trading lower after the company an offer and resale of up to 1,577,829 shares by the selling stockholders. The company reported Q3 financial results.

GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) reported quarterly losses of $(0.67) per share. This is a 98.98 percent increase over losses of $(65.78) per share from the same period last year.

Earnings

GRI Bio Q3 EPS $(0.67) Up From $(65.78) YoY

Offerings

GRI Bio Files For Offer And Resale By Selling Stockholders Of Up To 1,577,829 Shares Of Common Stock

<h3>Gainers</h3>
<ul>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) stock rose 50.3% to $0.64 during Friday's regular session. The market value of their outstanding shares is at $24.6 million. </li>
<li>ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) shares increased by 45.55% to $5.08. The market value of their outstanding shares is at $385.7 million. The company's, Q3 earnings came out yesterday. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares rose 27.44% to $1.86. The company's market cap stands at $2.5 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares rose 26.41% to $1.11. The company's market cap stands at $4.0 million. </li>
<li>Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) stock moved upwards by 25.53% to $38.94. The market value of their outstanding shares is at $130.7 million. The company's, Q1 earnings came out yesterday. </li>
<li>Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) stock increased by 20.73% to $14.88. The market value of their outstanding shares is at $1.2 billion. The company's, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) shares fell 35.1% to $1.26 during Friday's regular session. The market value of their outstanding shares is at $457.2 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock declined by 22.44% to $11.1. The market value of their outstanding shares is at $12.7 million. </li>
<li>Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) stock decreased by 21.57% to $17.23. The company's market cap stands at $1.5 billion. </li>
<li>Pulse Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) stock fell 14.0% to $14.99. The market value of their outstanding shares is at $918.7 million. The company's, Q3 earnings came out 2 days ago. </li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) shares decreased by 13.42% to $1.06. The company's market cap stands at $5.9 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares decreased by 12.38% to $0.5. The market value of their outstanding shares is at $36.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIX

ATHA

BFRI

CDXC

LXRX

MYGN

PDEX

PLSE

TOVX

XAIR

12 Health Care Stocks Moving In Friday's Intraday Session

Including $0.8M From Recent Warrant Exercise

GRI Bio Raises $13.9M In Gross Proceeds Since Start Of 2024; Funds Expected To Extend Cash Runway Into Mid-Q1 2025, Supporting Interim Data From Phase 2a Study Of GRI-0621 For Idiopathic Pulmonary Fibrosis (IPF) Treatment

<h3>Gainers</h3>
<ul>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares rose 92.5% to $0.3 during Wednesday's regular session. The company's market cap stands at $9.6 million. </li>
<li>Virax Biolabs Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>) stock rose 63.89% to $2.75. The market value of their outstanding shares is at $11.9 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock moved upwards by 59.31% to $2.56. The company's market cap stands at $437.7 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock rose 42.54% to $1.0. The company's market cap stands at $95.9 million. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares increased by 36.35% to $1.65. The company's market cap stands at $343.5 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock increased by 22.47% to $4.12. The market value of their outstanding shares is at $32.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Alto Neuroscience (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>) shares declined by 66.1% to $4.93 during Wednesday's regular session. The market value of their outstanding shares is at $132.9 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock fell 27.74% to $0.33. The market value of their outstanding shares is at $4.4 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares decreased by 26.44% to $0.4. The company's market cap stands at $5.4 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares fell 25.26% to $0.72. The market value of their outstanding shares is at $2.1 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock fell 25.18% to $1.07. The company's market cap stands at $2.1 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock fell 23.73% to $1.8. The market value of their outstanding shares is at $3.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANRO

BIVI

CNSP

CYCC

DBVT

ENSC

NUWE

SGMO

SLXN

TVGN

VRAX

12 Health Care Stocks Moving In Wednesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock moved upwards by 120.0% to $0.45 during Tuesday's regular session. The company's market cap stands at $6.2 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) stock rose 102.48% to $0.45. The market value of their outstanding shares is at $8.1 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares rose 90.15% to $2.87. The company's market cap stands at $7.4 million. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares increased by 41.29% to $1.29. The company's market cap stands at $268.6 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) shares increased by 31.15% to $3.45. The market value of their outstanding shares is at $27.5 million. </li>
<li>Werewolf Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOWL#NASDAQ">HOWL</a>) shares increased by 28.61% to $3.67. The market value of their outstanding shares is at $160.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) stock fell 30.5% to $0.33 during Tuesday's regular session. The market value of their outstanding shares is at $23.9 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) stock fell 28.74% to $0.94. The company's market cap stands at $2.7 million. </li>
<li>Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) stock decreased by 19.52% to $6.17. The company's market cap stands at $336.1 million. </li>
<li>VSee Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) stock decreased by 17.86% to $1.84. The market value of their outstanding shares is at $28.2 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares decreased by 17.15% to $5.22. The company's market cap stands at $3.4 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) stock declined by 16.65% to $0.65. The market value of their outstanding shares is at $16.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GNPX

HOWL

INAB

NDRA

SNSE

VSEE

VYGR

12 Health Care Stocks Moving In Tuesday's Intraday Session

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 150 points on Tuesday.
Following the market opening Tuesday, the Dow traded down 0.38% to 42,768.98 while the NASDAQ slipped 0.43% to 18,459.79. The S&amp;P 500 also fell, dropping, 0.49% to 5,825.05.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41426981/top-4-consumer-stocks-that-may-dip-this-quarter">Top 4 Consumer Stocks That May Dip This Quarter</a>
Leading and Lagging Sectors Consumer staples shares rose by 0.1% on Tuesday.
In trading on Monday, consumer discretionary shares fell by 0.9%.
Top Headline
General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) reported better-than-expected third-quarter results.
Quarterly adjusted earnings per share of $2.96 beats the street view of $2.43. Quarterly sales of $48.757 billion (+10.5%) beat the analyst consensus estimate of $44.585 billion.
The company raised 2024 adjusted EPS guidance from $9.50 – $10.50 to $10.00 – $10.50 (consensus $10.00).
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Genprex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares shot up 153% to $3.8400.</li>
<li>Shares of Ensysce Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) got a boost, surging 144% to $0.5015</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares were also up, gaining 50% to $1.3663 after the company announced the FDA approved an accelerated pathway for ST-920 in Fabry disease. A BLA submission is expected in 2025.</li>
</ul>
Equities Trading DOWN
<ul>
<li>GRI Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares dropped 29% to $0.9370.</li>
<li>Shares of JE Cleantech Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JCSE#NASDAQ">JCSE</a>) were down 25% to $1.67.</li>
<li>IN8bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) was down, falling 24% to $0.3598.</li>
</ul>
Commodities In commodity news, oil traded up 1.1% to $71.34 while gold traded up 0.6% at $2,754.70.
Silver traded up 2% to $34.760 on Tuesday, while copper rose 0.8% to $4.3940.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.4%, Germany's DAX fell 0.1% and France's CAC 40 fell 0.2%. Spain's IBEX 35 Index fell 0.5%, while London's FTSE 100 fell 0.2%.
Passenger car registrations in the European Union fell by 6.1% year-over-year to 809,163 units in September following a 18.3% decline in August.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 falling 1.39%, Hong Kong's Hang Seng Index gaining 0.1%, China's Shanghai Composite Index gaining 0.54% and India's BSE Sensex falling 1.15%.
The annual inflation rate in Hong Kong fell to 2.2% in September from 2.5% in the prior month.
Economics
No major economic reports are scheduled for release today.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41453972/top-3-defensive-stocks-that-may-keep-you-up-at-night-this-month">Top 3 Defensive Stocks That May Keep You Up At Night This Month</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

JCSE

Dow Falls Over 150 Points; General Motors Tops Q3 Views

<h3>Gainers</h3>
<ul>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock increased by 134.8% to $0.48 during Tuesday's pre-market session. The market value of their outstanding shares is at $6.7 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) stock rose 118.54% to $3.3. The market value of their outstanding shares is at $8.5 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock moved upwards by 51.51% to $0.5. The market value of their outstanding shares is at $3.7 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares rose 43.17% to $3.25. The market value of their outstanding shares is at $1.6 million. </li>
<li>Addex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) shares rose 24.21% to $12.79. The market value of their outstanding shares is at $13.6 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares increased by 20.55% to $0.29. The market value of their outstanding shares is at $3.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares fell 24.7% to $0.99 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.9 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) stock declined by 21.03% to $0.62. The market value of their outstanding shares is at $15.4 million. </li>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) shares declined by 14.11% to $0.41. The company's market cap stands at $29.5 million. </li>
<li>Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) shares declined by 11.32% to $312.98. The market value of their outstanding shares is at $9.7 billion. The company's, Q3 earnings came out yesterday. </li>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) shares fell 9.23% to $5.02. The market value of their outstanding shares is at $210.8 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares decreased by 8.56% to $0.64. The market value of their outstanding shares is at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADXN

APVO

HURA

MEDP

PTIX

<h3>Gainers</h3>
<ul>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock moved upwards by 134.8% to $0.48 during Tuesday's pre-market session. The company's market cap stands at $6.7 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) stock rose 118.54% to $3.3. The company's market cap stands at $8.5 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock rose 51.51% to $0.5. The market value of their outstanding shares is at $3.7 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares rose 43.17% to $3.25. The market value of their outstanding shares is at $1.6 million. </li>
<li>Addex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) shares increased by 24.21% to $12.79. The company's market cap stands at $13.6 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares moved upwards by 20.55% to $0.29. The market value of their outstanding shares is at $3.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares fell 24.7% to $0.99 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.9 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) stock decreased by 21.03% to $0.62. The market value of their outstanding shares is at $15.4 million. </li>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) shares decreased by 14.11% to $0.41. The market value of their outstanding shares is at $29.5 million. </li>
<li>Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) shares decreased by 11.32% to $312.98. The market value of their outstanding shares is at $9.7 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) stock fell 9.23% to $5.02. The company's market cap stands at $210.8 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock fell 8.56% to $0.64. The company's market cap stands at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Shares of iRhythm Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) rose sharply in today's pre-market trading after the company announced that it was granted FDA clearance for its 510(k) submission related to prior design changes <a href="https://www.benzinga.com/quote/IRTC">made to the Zio AT device.</a>
iRhythm Technologies shares jumped 20.5% to $74.80 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Genprex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) rose 145.7% to $3.71 in pre-market trading after jumping around 260% on Monday.</li>
<li>SRM Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRM#NASDAQ">SRM</a>) gained 82.1% to $1.34 in pre-market trading.</li>
<li>TC Biopharm (Holdings) Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares surged 77.5% to $4.03 in pre-market trading after declining 55% on Monday.</li>
<li>Urgent.ly Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULY#NASDAQ">ULY</a>) rose 44.5% to $0.9870 in pre-market trading.</li>
<li>Inspire Veterinary Partners, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares rose 42.2% to $0.47 in pre-market trading after jumping around 34% on Monday.</li>
<li>Ensysce Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares jumped 39.1% to $0.2864 in pre-market trading after gaining around 15% on Monday.</li>
<li>MarketWise, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKTW#NASDAQ">MKTW</a>) gained 24.9% to $0.7315 in pre-market trading. MarketWise's 13G filing showed BlackRock reported a 5.2% stake in the co as of Sept. 30.</li>
<li>Addex Therapeutics Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) climbed 21.7% to $12.95 in pre-market trading.</li>
<li>Dana Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAN#NYSE">DAN</a>) gained 6.9% to $11.25 in pre-market trading after declining around 6% on Monday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>IN8bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) shares dipped 21.3% to $0.3737 in pre-market trading after jumping around 75% on Monday.</li>
<li>GRI Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares fell 21.2% to $1.04 in pre-market trading after announcing exercise of warrants.</li>
<li>DMC Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOOM#NASDAQ">BOOM</a>) fell 18% to $10.60 in pre-market trading after the company cut its third-quarter guidance and announced it is no longer actively marketing DynaEnergetics and NobelClad.</li>
<li>Sensei Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) fell 15% to $0.6633 in today's pre-market trading after jumping over 78% on Monday.</li>
<li>Medpace Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) fell 11.3% to $313.00 in pre-market trading after the company reported worse-than-expected third-quarter sales results.</li>
<li>BioVie Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) shares fell 10.7% to $2.35 in pre-market trading. BioVie announced the pricing of registered direct offering and concurrent private placement priced at-the-market under Nasdaq rules.</li>
<li>Notable Labs, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTBL#NASDAQ">NTBL</a>) shares declined 9.3% to $0.3111 in pre-market trading after gaining over 10% on Monday.</li>
<li>Genuine Parts Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>) declined 9.2% to $130.00 in pre-market trading after reporting weak quarterly earnings.</li>
<li>Knightscope, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSCP#NASDAQ">KSCP</a>) shares declined 8.9% to $12.07 in pre-market trading after surging 19% on Monday.</li>
<li>ATN International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNI#NASDAQ">ATNI</a>) shares fell 8.1% to $29.30. ATN International will release third quarter results on Tuesday, Oct. 29.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41429862/this-analyst-with-85-accuracy-rate-sees-around-11-upside-in-netflix-here-are-5-stock-picks-for-last">This Analyst With 85% Accuracy Rate Sees Around 11% Upside In Netflix &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Pre-Market Outlook

ATNI

BOOM

IRTC

KSCP

MKTW

NTBL

Why iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Press Releases

Top Innovation Stocks Surge: PRSO, SYTA, SAVE, ISPC, GRI, BIVI – Must-Watch Stocks This Week

GRI Bio Announces Exercise of Warrants

GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis

GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

GRI Bio to Participate in the Virtual Investor Closing Bell Series

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

Events

Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand

GRI Bio, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Comments

GRI Bio

GRI Bio (GRI) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル